{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:56:00Z","timestamp":1790009760829,"version":"4.0.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":599,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.cmi.2022.05.013","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T02:28:04Z","timestamp":1652840884000},"page":"1291.e7-1291.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["In\u00a0vitro activity of olorofim against Aspergillus fumigatus sensu lato clinical isolates: activity is retained against isolates showing resistance to azoles and\/or amphotericin B"],"prefix":"10.1016","volume":"28","author":[{"given":"Pilar","family":"Escribano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Reigadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Guinea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.05.013_bib1","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1093\/jac\/dkz258","article-title":"Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients","volume":"74","author":"Resendiz-Sharpe","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.05.013_bib2","doi-asserted-by":"crossref","first-page":"1170.e1","DOI":"10.1016\/j.cmi.2020.09.042","article-title":"Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain","volume":"27","author":"Escribano","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.05.013_bib3","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2022.05.013_bib4","first-page":"122","article-title":"Review of the novel investigational antifungal olorofim","volume":"6","author":"Wiederhold","year":"2020","journal-title":"J\u00a0Fungi (Basel)"},{"key":"10.1016\/j.cmi.2022.05.013_bib5","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/jac\/dkz078","article-title":"In\u00a0vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies","volume":"74","author":"Rivero-Menendez","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.05.013_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00632-19","article-title":"cyp51A mutations, extrolite profiles, and antifungal susceptibility in clinical and environmental isolates of the Aspergillus viridinutans species complex","volume":"63","author":"Talbot","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.05.013_bib7","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1093\/jac\/dkx177","article-title":"In\u00a0vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates","volume":"72","author":"Buil","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.05.013_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00487-18","article-title":"EUCAST determination of olorofim (F901318) susceptibility of mold species, method validation, and MICs","volume":"62","author":"Jorgensen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.05.013_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01527-20","article-title":"Olorofim susceptibility testing of 1,423 Danish mold isolates obtained in 2018-2019 confirms uniform and broad-spectrum activity","volume":"65","author":"Astvad","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.05.013_bib10","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/jac\/dkaa562","article-title":"In\u00a0vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species","volume":"76","author":"Singh","year":"2021","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.05.013_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02546-20","article-title":"Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical Aspergillus fumigatus isolates, and review of azole resistance phenotype and genotype epidemiology in China","volume":"65","author":"Su","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.05.013_bib12","first-page":"378","article-title":"In\u00a0vitro activity of novel antifungal olorofim against filamentous fungi and comparison to eight other antifungal agents","volume":"7","author":"Georgacopoulos","year":"2021","journal-title":"J\u00a0Fungi (Basel)"},{"key":"10.1016\/j.cmi.2022.05.013_bib13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/22221751.2022.2034485","article-title":"Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance","volume":"11","author":"Buil","year":"2022","journal-title":"Emerg Microbe. Infect"},{"key":"10.1016\/j.cmi.2022.05.013_bib14","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.cmi.2020.06.007","article-title":"How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)","volume":"26","author":"Arendrup","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.05.013_bib15","article-title":"EUCAST definitive document E.Def 9.4. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds","author":"Guinea","year":"2022","journal-title":"EUCAST"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22002695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22002695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:32:06Z","timestamp":1761118326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X22002695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1198743X22002695"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.05.013","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0vitro activity of olorofim against Aspergillus fumigatus sensu lato clinical isolates: activity is retained against isolates showing resistance to azoles and\/or amphotericin B","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}